US FDA extends review of KalVista's swelling disorder drug due to heavy workload

Kalvista Pharmaceuticals

13/06/2025 21:12

June 13 (Reuters) - The U.S. Food and Drug Administration extended the review of KalVista Pharmaceuticals' KALV.O drug for a type of hereditary swelling disorder due to heavy workload and limited resources, the company said on Friday.

The FDA indicated that it expects to deliver a decision within approximately four weeks, KalVista said.

 (Reporting by Puyaan Singh in Bengaluru; Editing by Pooja Desai)

 ((Puyaan.Singh@thomsonreuters.com;))